Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
Delayed Japan Exchange  -  01:00:00 2023-02-06 am EST
7631.00 JPY   -3.02%
03:56aJefferies Adjusts Eisai's Price Target to 8,000 Yen From 10,000 Yen, Keeps at Hold
MT
02/04Why a new Alzheimer's drug is having a slow US debut
AQ
02/03Interim Report for the period October - December 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eisai shares plunge 10% in Tokyo after report of death in Alzheimer's trial

11/28/2022 | 07:57pm EST

TOKYO, Nov 29 (Reuters) - Shares in Japanese drugmaker Eisai Co headed for their biggest plunge in more than a year on Tuesday after a report that a woman in a trial of the company's Alzheimer's disease treatment died.

A woman receiving lecanemab, an experimental drug developed by Eisai and its U.S. partner Biogen Inc, recently died from a brain haemorrhage, research paper publisher Science.org reported on Sunday.

That would mark a second fatality in a lecanemab trial, following the death of a man in his 80s in June, according to a report by the health journal STAT.

Eisai's shares sank 10% to 8,595 yen, leading decliners on the benchmark Nikkei index, which slid 0.5% in the morning session. Shares in Biogen sank 4.3% on Monday.

Eisai, in response to a request for comment on the report, said it cannot provide any information about specific patients or comment on information that was provided by other sources. Biogen did not immediately respond to a request for comment.

Eisai and Biogen shares have been on a roller coaster in recent years on prospects for their candidates to battle dementia.

The companies' previous drug Aduhelm won approval from the U.S. Food and Drug Administration in 2021, but its use has been limited due to concerns over its price and effectiveness.

Lecanemab was shown to slow cognitive and functional decline in a large trial of patients in the early stages of Alzheimer's disease, Eisai and Biogen said in September. (Reporting by Rocky Swift in Tokyo and Raghav Mahobe and Khushi Mandowara in Bengaluru; Editing by Cynthia Osterman)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -1.35% 283.63 Delayed Quote.2.42%
EISAI CO., LTD. -3.02% 7631 Delayed Quote.-9.59%
NIKKEI 225 0.67% 27693.65 Real-time Quote.5.42%
All news about EISAI CO., LTD.
03:56aJefferies Adjusts Eisai's Price Target to 8,000 Yen From 10,000 Yen, Keeps at Hold
MT
02/04Why a new Alzheimer's drug is having a slow US debut
AQ
02/03Interim Report for the period October - December 2022
AQ
01/31Eisai-Biogen Gets Priority Review for Alzheimer's Drug in Japan
MT
01/30Global markets live: Toyota, Unilever, Bayer, Goldman Sachs, Biogen...
MS
01/30It's all about central banks this week
MS
01/30Eisai-Biogen Partnership Pursues Marketing Authorization of Alzheimer's Drug in Europe
MT
01/30Biogen, Eisai Drug Lecanemab Gets Priority Review Status in Japan
MT
01/29Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen
RE
01/29Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen
RE
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Financials
Sales 2023 743 B 5 679 M 5 679 M
Net income 2023 57 255 M 437 M 437 M
Net cash 2023 223 B 1 703 M 1 703 M
P/E ratio 2023 40,0x
Yield 2023 2,04%
Capitalization 2 258 B 17 244 M 17 244 M
EV / Sales 2023 2,74x
EV / Sales 2024 2,58x
Nbr of Employees 11 322
Free-Float 93,3%
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 7 869,00 JPY
Average target price 9 063,64 JPY
Spread / Average Target 15,2%
EPS Revisions
Managers and Directors
Haruo Naito Manager-Research & Development Promotions
Tatsuyuki Yasuno Manager-Corporate Planning
Yasuhiko Katoh Chairman
Keisuke Naito Executive Officer & Head-Global IT Headquarters
Yasushi Okada Manager-Business Planning
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.-9.59%17 244